Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results-Reference-Cited by-同舟云学术

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Published:2023-01-23 Issue:2 Volume:29 Page:422-429
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Mailankody Sham^ORCID,Matous Jeffrey V.,Chhabra Saurabh^ORCID,Liedtke Michaela,Sidana Surbhi^ORCID,Oluwole Olalekan O.,Malik Shahbaz,Nath Rajneesh,Anwer Faiz,Cruz Jose Carlos,Htut Myo,Karski Erin E.,Lovelace Wade,Dillon Myles,Butz Eric,Ying Wendy,Balakumaran Arun,Kumar Shaji K.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-02182-7.pdf

Reference37 articles.

1. Kumar, S. K. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26, 149–157 (2012).

2. Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048–2060 (2013).

3. Moreaux, J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148–3157 (2004).

4. Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689–694 (2004).

5. Blenrep (belantamab mafodotin-blmf) [package insert] (GlaxoSmithKline Intellectual Property Development Ltd, 2022).

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

2. Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes;Frontiers in Immunology;2024-09-10

3. Recent updates on allogeneic CAR-T cells in hematological malignancies;Cancer Cell International;2024-09-03

4. CAR-T in cancer therapeutics and updates;Journal of the National Cancer Center;2024-09

5. Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances;Best Practice & Research Clinical Haematology;2024-09